A cohort study on the safety of bevacizumab in combination with neoadjuvant chemotherapy in the initial treatment of advanced ovarian cancer using a Japanese healthcare database

A cohort study on the safety of bevacizumab in combination with neoadjuvant chemotherapy in the initial treatment of advanced ovarian cancer using a Japanese healthcare database - A cohort study on the safety of bevacizumab in combination with neoadjuvant chemotherapy in the initial treatment of advanced ovarian cancer using a Japanese healthcare database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041175

Enrollment

48000

Registered

2020-07-27

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced ovarian cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with ovarian cancer, fallopian tube cancer or peritoneal cancer from April 1, 2008 to January 29, 2020

Exclusion criteria

Exclusion criteria: Patients with cancer other than ovarian cancer, fallopian tube cancer or peritoneal cancer

Design outcomes

Primary

Measure	Time frame
The incidence of gastrointestinal perforation of neoadjuvant chemotherapy in combination with or without bevacizumab in the initial treatment of advanced ovarian cancer, and the risk ratio and risk difference of bevacizumab in combination with neoadjuvant chemotherapy compared to chemotherapy alone	—

Countries

Japan

Contacts

Public ContactCo., Ltd. Chugai Pharmaceutical

Medical Affairs Div. Medical Science Dept.

cma-clinicaltrial@chugai-pharm.co.jp03-3273-0866

Outcome results